Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAUTIKA1: Multiple Therapies in Biomarker-selected Resectable NSCLC
NCT04302025Phase 2Recruiting
- Sponsor
- Genentech
- Start
- Nov 2020
- Primary completion
- Nov 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label trial of alectinib, entrectinib, vemurafenib, cobimetinib, pralsetinib and 2 more in non-small cell lung cancer (NSCLC) (7 cohorts), sponsored by Genentech. Primary endpoints: Major Pathologic Response at Week 8, Pathological Complete Response at Week 8 and 2 more. Started Nov 2020; status: recruiting.
02
Drugs
alectinibentrectinibvemurafenibcobimetinibpralsetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04302025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04302025.